United States Anti-Doping Agency Reauthorization Act

United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5614 Introduced in House (IH)]

113th CONGRESS
  2d Session
                                H. R. 5614

  To reauthorize the United States Anti-Doping Agency, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 18, 2014

    Mr. Johnson of Ohio (for himself and Mr. Tonko) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
  To reauthorize the United States Anti-Doping Agency, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``United States Anti-Doping Agency 
Reauthorization Act''.

SEC. 2. PROHIBIT PERFORMANCE-ENHANCING METHODS.

    Section 701 of title VII of the Office of National Drug Control 
Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is amended--
            (1) in subsection (a), by striking paragraph (4); and
            (2) in subsection (b)--
                    (A) in paragraph (1), by inserting ``and be 
                recognized worldwide as the independent national anti-
                doping organization for the United States'' after 
                ``Committee'';
                    (B) in paragraph (2), by striking ``, or 
                performance-enhancing genetic modifications 
                accomplished through gene-doping'' and inserting ``or 
                prohibited performance-enhancing methods adopted by the 
                Agency'';
                    (C) in paragraph (3), by striking ``, or 
                performance-enhancing genetic modifications 
                accomplished through gene-doping'' and inserting ``or 
                prohibited performance-enhancing methods adopted by the 
                Agency'';
                    (D) in paragraph (4), by striking ``and the 
                prevention of use of performance-enhancing drugs, or 
                performance-enhancing genetic modifications 
                accomplished through gene-doping by United States 
                amateur athletes; and'' and inserting ``, and the 
                prevention of use by United States amateur athletes of 
                performance-enhancing drugs or prohibited performance-
                enhancing methods adopted by the Agency.''; and
                    (E) by striking paragraph (5).

SEC. 3. AUTHORIZATION OF APPROPRIATIONS.

    Section 703 of title VII of the Office of National Drug Control 
Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read 
as follows:

``SEC. 703. AUTHORIZATION OF APPROPRIATIONS.

    ``There are authorized to be appropriated to the United States 
Anti-Doping Agency--
            ``(1) for fiscal year 2014, $11,300,000;
            ``(2) for fiscal year 2015, $11,700,000;
            ``(3) for fiscal year 2016, $12,300,000;
            ``(4) for fiscal year 2017, $12,900,000;
            ``(5) for fiscal year 2018, $13,500,000;
            ``(6) for fiscal year 2019, $14,100,000; and
            ``(7) for fiscal year 2020, $14,800,000.''.
                                 <all>